Cryptococcus gattii in Patients with Lymphoid Neoplasms: An Illustration of Evolutive Host-Fungus Interactions

Olivier Paccoud1, Marie-Elisabeth Bougnoux2, Marie Desnos-Ollivier3

  • 1University of Paris, Necker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), 75015 Paris, France.

Insights

Cryptococcus gattii (CG) meningitis is rare in lymphoid neoplasms. This case highlights the need for awareness and careful antifungal management in immunocompromised patients, especially those on targeted therapies.

Area of Science:

  • Infectious Diseases
  • Mycology
  • Hematology

Background:

  • Cryptococcus gattii (CG) outbreaks in North America reveal distinct virulence and epidemiology compared to Cryptococcus neoformans.
  • CG infections are increasingly reported in diverse patient groups, yet remain uncommon in lymphoid neoplasms.
  • Limited data exists on CG epidemiology and management within the context of hematological malignancies.

Purpose of the Study:

  • To report a case of autochthonous CG meningitis in a patient with chronic lymphocytic leukemia (CLL) treated with ibrutinib.
  • To review the clinical epidemiology of CG infections in patients with lymphoid neoplasms.
  • To summarize host responses to CG and potential treatment challenges in the hematological setting.

Main Methods:

  • Case report of a patient with CLL and CG meningitis.
  • Literature review of clinical epidemiology of CG infections in lymphoid neoplasms.
  • Summary of current knowledge on host responses and antifungal management in immunocompromised patients.

Main Results:

  • A rare case of CG meningitis occurred in a patient with CLL on ibrutinib therapy in France.
  • CG infections in lymphoid neoplasms are infrequent but potentially severe.
  • Management involves complex interactions between pathogen, host immunity, and potential drug-drug interactions with cancer therapies.

Conclusions:

  • CG meningitis is an emerging concern in patients with lymphoid neoplasms, particularly those on targeted therapies like ibrutinib.
  • Enhanced clinical vigilance and tailored antifungal strategies are crucial for managing CG in this vulnerable population.
  • Future guidelines must address the complexities of antifungal treatment and drug interactions in the onco-hematological setting.

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
530
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
234
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
7.9K